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Abstract. The first objective of the present study was to 
investigate fatigue severity in patients diagnosed with bone 
and soft tissue tumors prior to the surgical treatment of the 
tumor and 6 months post-operatively. The second objective 
was to determine which variables are associated with severe 
fatigue. Patients diagnosed with benign or low-grade malig-
nant bone and soft tissue tumors, undergoing surgical therapy 
for the tumor only, were included in this study. The control 
group contained patients scheduled for knee arthroscopy for 
suspected meniscus tears. Fatigue, pain, anxiety and self‑effi-
cacy were measured pre-operatively and after 6 months and 
each patient wore an actometer to quantify physical activity. 
In the tumor group of 43 patients, 35% were severely fatigued 
pre-operatively and 33% post-operatively. The tumor group 
reported a significantly higher level of anxiety. No differences 
were observed in pain, physical limitations, self‑efficacy or 
actometer scores. Multiple regression analysis of the tumor 
group revealed that higher pain scores, higher state anxiety 
and lower self‑efficacy were asssociated with fatigue severity. 
In the control group of 24 knee arthroscopy patients, the 
percentage of severely fatigued patients decreased from 
38% (n=9) prior to treatment to 29% (n=7) 6 months later. A 
substantial number of patients were severely fatigued in both 
the tumor group and the knee arthroscopy group. Self‑efficacy, 
pain and anxiety appear to be the most important variables 
associated with fatigue severity in tumor patients prior to 
surgery.
Introduction
In the majority of studies concerning cancer-associated 
fatigue, no clear association between fatigue and the type of 
cancer treatment has been revealed (1,2). Severe fatigue was 
not only observed in patients with malignant tumors but also 
in patients treated for benign bone tumors (3,4). Severe fatigue 
remained present in over a quarter of patients after a 2-year 
disease-free period and appears to be associated with tumor 
recurrence, less patient optimism, lower self-efficacy and 
increased somatization. It is unclear to what extent the fatigue 
already existed prior to the treatment of the tumor. 
While fatigue is known to be an important factor influ-
encing the quality of life of patients, little is known about the 
development of fatigue before, during or after tumor treatment 
and its contributing factors. Few studies have measured fatigue 
in patients before or during the treatment of a tumor (5-7). 
Therefore, the first objective of the present study was to 
investigate fatigue severity in patients diagnosed with benign 
or low-grade malignant bone and soft tissue tumors prior to the 
surgical treatment of the tumor and 6 months post-operatively. 
The second objective was to determine which variables within 
the tumor group are significantly associated with fatigue 
severity. Variables which were expected to contribute to severe 
fatigue were selected, including physical limitations, physical 
(in)activity, pain, self‑efficacy and anxiety. It was expected 
that decreased levels of physical activity caused by local pain 
from the tumor and weight-bearing restrictions, as well as the 
more physical limitations, would be associated with a higher 
level of fatigue (8). Anxiety was expected to be higher in the 
tumor group, both in benign and malignant tumors, due to the 
knowledge of having a tumor, the stress of the surgical treat-
ment and the fear of local recurrence. A higher pain score and 
level of anxiety were expected to be associated with a higher 
level of fatigue. An association between higher self‑efficacy 
and lower fatigue severity was demonstrated in a previous 
study (6).
The level of fatigue was assessed before the patients 
underwent surgery (the only tumor treatment) and 6 months 
post-operatively. Fatigue severity and possible associated 
factors in the tumor patients were compared with those of 
patients undergoing knee arthroscopy for suspected meniscus 
tears. The knee arthroscopy patients were selected as the 
control group, since these patients suffer from knee pain and 
decreased physical activity but do not have the psychological 
stress of a tumor diagnosis. The level of fatigue in the arthros-
copy and tumor groups was also compared with published data 
from healthy controls.
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Patients and methods
Patients. Consecutive patients recently diagnosed with benign 
or low-grade malignant bone and soft tissue tumors at the 
Department of Orthopaedic Surgery of the Radboud University 
Medical Centre Nijmegen (Nijmegen, The Netherlands) aged 
between 18 and 75 years and undergoing surgical therapy for 
the tumor only were asked to participate in the present study. 
Patients receiving chemotherapy or radiotherapy as adjuvant 
treatments were excluded from the study. Other exclusion criteria 
included previous treatment for cancer and severe co-morbidity 
causing fatigue. The control group contained patients under-
going knee arthroscopy for suspected meniscus tears, aged 
between 18 and 75 years, without severe co-morbidity causing 
fatigue. The tumor and the arthroscopy groups received the 
same assessment and this was performed prior to surgery and 6 
months later. Permission for this study was given by the ethics 
committee of the medical centre. A written informed consent 
was signed by all participating patients.
Assessment
Fatigue severity. Fatigue was measured with the fatigue severity 
subscale of the checklist individual strength (CIS) (2,9). This 
subscale contains 8 items scored on a 7-point Likert scale. 
Scores range between 8 (no fatigue) and 56 (severe fatigue). 
A score of ≥35 points indicates severe fatigue. This score is 
higher than the mean plus two standard deviations of a healthy 
control group (9,10). The CIS fatigue subscale has been used in 
studies concerning chronic fatigue syndrome and post-cancer 
fatigue and measures fatigue severity over the past 2 weeks. 
Since this questionnaire has a cut-off point for severe fatigue, 
it may be used to identify severe fatigue in individual patients 
and also for prevalence estimates in populations. Normative 
data are available for healthy controls. In the present study, the 
fatigue scores of the 2 patient groups were compared with the 
fatigue scores of a group of 53 healthy adults with a mean age 
of 37.1 years (SD, 11.5) (10).
Pain. Current pain was measured with an 11-point numeric 
rating scale (NRS) with a score of 0 for no pain and 10 for 
severe pain. The pain subscale of the SF-36, in which patients 
have to indicate the magnitude of their pain symptoms and the 
impairment to daily functioning caused by this pain, was used 
to assess the impact of pain. Scores range between 0 and 100 
(100 = no pain and no impairments due to pain; 0 = maximal 
pain and maximal impairment due to pain) (11,12).
Physical limitations. Physical limitations were measured 
with the SF-36 subscale of physical functioning. This score 
ranges between 0 (very low physical functioning) and 100 
(optimal physical functioning) (11,12). 
Anxiety. The level of anxiety was measured with 
the Spielberger State-Trait Anxiety Inventory version Y 
(STAI-form Y) (13,14). Only the subscale state anxiety was 
used, since the present level of anxiety was relevant to the 
present study. Scores range between 20 and 80 and a higher 
score reflects a higher level of anxiety. 
General self‑efficacy. General self‑efficacy, a general sense 
of personal competence and effectiveness, was measured 
with the general self‑efficacy scale. The total score ranges 
between 10 and 40 and a higher score reflects a higher sense 
of control (15,16).
Physical activity. An actometer (Actilog V3.0), a 
motion-sensing device worn at the ankle for 12 consecu-
tive days and nights, was used to quantify physical activity. 
The actometer detects movements of the leg (e.g., during 
walking or climbing stairs). A general physical activity score 
that expressed the mean activity level over this period as the 
mean number of accelerations per 5-min intervals was calcu-
lated (17). Higher scores indicate a higher level of physical 
activity. Self-reported physical activity was measured on an 
11-point NRS, with a score of 0 for ‘not physically active’ and 
10 for ‘physically very active’. 
Statistical analysis. Statistical analysis was performed using 
SPSS software (version 16.0). Descriptive statistics were used 
for description of the sample. The differences in fatigue, pain, 
physical activity, anxiety and self‑efficacy between the tumor 
and arthroscopy group were tested using t-tests for indepen-
dent samples. A t-test for independent samples was also used 
to compare the levels of fatigue of the 2 patient groups with a 
group of healthy controls. Pearson correlation analyses were 
used to determine the associations between fatigue severity 
and demographic, psychological and/or physical variables in 
the tumor group. 
The variables that significantly correlated with fatigue 
severity were used as predictors in a multiple regression (back-
ward method) with fatigue severity as the dependent variable. 
Only significant variables were entered in the multiple regres-
sion. As the sample size was expected to be rather small, this 
step was performed to limit the number of predictors. P<0.05 
in the t-test and correlations were considered to indicate statis-
tically significant differences. For the multiple regression, a 
P-value of 0.10 was used as the criterion for the removal of 
the variable from the regression. The significant predictors 
resulting from the regression analysis were considered to be 
possible determinants of fatigue.
Results
Patients. In the tumor patient group, 48 patients were included 
prior to the treatment of the tumor. At the 6-month follow-up, 
four patients refused to complete the assessment and were 
excluded from the analysis. One patient was also excluded 
due to a cerebrovascular accident during treatment. Of the 
remaining 43 patients, 20 were male (47%) and 23 female 
(53%). The mean age was 41.5 years (range, 19-67 years) and the 
tumors were located in the upper extremity (40%) or the lower 
extremity (60%). Treatment consisted of local excision (soft 
tissue tumors, osteochondroma) or curettage and cryosurgery 
(aneurysmal bone cysts, giant cell tumor, fibrous dysplasia, 
aggressive enchondroma, low-grade chondrosarcoma). One 
patient in the follow-up period underwent a second surgery 
to explore the previously operated area for suspected local 
recurrence but no local recurrence was identified. All other 
tumor patients were disease-free during the follow-up period. 
In the control group of knee arthroscopy patients, 24 patients 
completed the assessment before and 6 months after the 
arthroscopy. There were 13 males (54%) and 11 females (46%) 
in this group with a mean age of 43.1 years (range, 23-68 years). 
During the 6-month follow-up, 2 patients underwent a second 
surgery due to medial gonarthrosis, 1 patient underwent a high 
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tibial osteotomy and 1 patient received an unicondylar knee 
prosthesis. 
Fatigue severity in the tumor and knee arthroscopy group. In 
the tumor group, 35% of the patients were severely fatigued 
prior to treatment and 33% at the 6-month follow-up. The 
CIS fatigue score decreased significantly between pre‑ and 
post-operative assessment in the tumor and arthroscopy 
groups (Table I). The decrease over time in the CIS score was 
not significantly different between the tumor and arthroscopy 
groups [F (1.65)=0.326; P=0.570]. The mean CIS score at 
follow-up of the 2 groups was markedly higher than that of the 
healthy controls: 26.1 (SD, 13.7) in the tumor group and 24.4 
(SD, 12.6) in the arthroscopy group, compared with a mean 
CIS-fatigue score of 17.3 (SD, 10.1) in the healthy control 
group (6). 
In the arthroscopy group 9 patients (38%) were severely 
fatigued prior to the surgery. Of these 9 patients, four remained 
severely fatigued 6 months later without any physical prob-
lems associated with the surgery. The 3 knee arthroscopy 
patients that developed severe fatigue during or after treatment 
all underwent a second knee surgery or had persistent knee 
complaints. In the tumor patient group, only one patient under-
went a second surgery and all patients were without evidence 
of disease 6 months after treatment. 
Pain, physical limitations, physical activity, anxiety and 
self‑efficacy in both patient groups. Scores for pain and 
anxiety decreased over time, whereas the actometer and phys-
ical functioning scores increased. No significant differences 
were observed between the tumor and arthroscopy groups 
with respect to the changes in these variables. The score for 
self‑efficacy did not change over time as expected. Pre‑ and 
post-operative actometer scores were not compared, due to the 
small sample size of the pre-operative group (Table I). 
Correlation of fatigue with other variables in the tumor 
patients. In the tumor group the NRS pain score, SF-36 pain, 
SF‑36 physical functioning, anxiety and self‑efficacy corre-
lated significantly with fatigue severity (Table II). The anxiety 
score in the tumor patient group did not significantly differ 
between a benign and malignant diagnosis (t-test, P=0.405). 
Multiple regression. Multiple regression analysis was used 
to identify predictors of severe fatigue in the tumor group 
6 months after treatment (Table III). Factors significantly 
correlated with the CIS fatigue score in the previous study 
were entered in the analysis (anxiety at follow-up SF-36 pain 
at follow‑up and self‑efficacy at follow‑up), as well as the CIS 
fatigue score before treatment.
Analysis revealed that higher CIS fatigue scores prior to 
treatment and higher state anxiety at follow-up were predictors 
of fatigue severity that explained ~55% of the variance.
Table I. CIS fatigue, pain, anxiety, self‑efficacy and physical functioning scores before and 6 months after surgical treatment. 
 Tumor (n=43), mean (SD) Arthroscopy (n=24), mean (SD)
 --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
Characteristic Pre-op Follow-up P-value Pre-op Follow-up P-value
CIS fatigue 29.7 (14.2) 26.1 (13.7) 0.023 29.7 (13.1) 24.4 (12.6) 0.090
Pain (NRS) 2.7 (2.5) 2.1 (2.1) 0.061 2.3 (3.1) 1.8 (2.2) 0.445
SF-36 pain 57.0 (26.2) 71.8 (23.7) 0.000 66.5 (22.0) 82.8 (16.4) 0.007
SF-36 physical functioning 60.5 (26.8) 72.6 (23.7) 0.000 61.9 (20.7) 82.9 (18.7) 0.000
State anxiety 37.5 (10.5) 32.9 (10.1) 0.006 30.1 (7.7) 29.0 (9.9) 0.498
Self‑efficacy 32.1 (4.5) 31.8 (4.8) 0.763 34.3 (4.3) 34.2 (4.3) 0.951
CIS, checklist individual strength; NRS, numeric rating scale; SD, standard deviation. Pre-op, pre-operatively. 
Table II. Correlation of variables with fatigue severity (CIS 




SF-36 physical functioning -0.338b
State anxiety 0.355b
Self‑efficacy ‑0.343b 
Physical activity (self-reported NRS) -0.215
Actometer -0.026
aPearson-r; bP<0.05; cP<0.01; CIS, checklist individual strength; 
NRS, numeric rating scale.
Table III. Results of multiple regression analysis to determine 
the contribution of variables to fatigue severity (CIS fatigue) 
in tumor patients 6 months after surgical treatment.
Predictor B Beta P-value
Constant -2.903  
State anxiety 0.401 0.302 0.033
(follow-up)   
CIS-fatigue (pre-op) 0.505 0.539 0.000
R2 adjusted 0.553  
CIS, checklist individual strength. Pre-op, pre-operatively. B, base-
line, Beta, at follow-up.
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Discussion
The primary objective of the present study was to determine 
the level of fatigue in patients diagnosed with benign and 
low-grade malignant bone and soft tissue tumors prior to the 
surgical treatment of the tumor and 6 months post-operatively. 
It was revealed that a substantial number of patients (38%) were 
severely fatigued. Six months after surgical treatment, 33% of 
the patients remained severely fatigued. When this group of 
severely fatigued patients was analyzed, it was apparent that 
the majority of the severely fatigued patients before treatment 
remained fatigued 6 months later. This severe fatigue cannot 
be explained by the physical condition of the patients, since 
all lacked evidence of disease and no complications from 
the surgical treatment occurred. Multiple regression analysis 
confirmed that a high CIS fatigue score prior to treatment was 
the most successful predictor of severe fatigue 6 months later. 
The CIS fatigue score decreased significantly over time but 
the percentage of patients severely fatigued before and after 
treatment remained similar. 
In the knee arthroscopy group, severe fatigue was present 
to the same extent as in the tumor group prior to treatment. 
This supports the theory that severe fatigue is not induced by 
the tumor itself but by symptoms caused by the tumor or a 
meniscus tear, including pain, restricted physical activity and 
anxiety. In the arthroscopy group, severe fatigue at follow-up 
was associated with a second surgery or persistent knee 
complaints in approximately half of the patients. 
It appears that severe fatigue is a symptom that develops 
prior to treatment and, if present at the clinical diagnosis, often 
persists over time. Interventions for persistent fatigue following 
cancer treatment, such as a physical training programs or 
cognitive behavioral therapy (18-20) have been demonstrated 
to be successful at reducing fatigue severity. With the results of 
the present study revealing that the majority of patients suffer 
from severe fatigue prior to treatment, we suggest that it may 
be useful to perform a screen for pre-existing fatigue severity 
prior to diagnosis and begin intervention for severe fatigue as 
early as possible after treatment.
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